Sarepta price target lowered to $110 from $182 at Piper Sandler

Piper Sandler lowered the firm’s price target on Sarepta (SRPT) to $110 from $182 and keeps an Overweight rating on the shares. The firm is lowering its Elevidys sales estimates based on results from a survey it conducted with 20 neurologists to better understand potential implications of Elevidys’ recent safety update on prescribing patterns and to get a better sense for provider sentiment and market outlook. While 40% of respondents state no impact from patient death, 60% of respondents claim the safety event would impact prescribing for Elevidys. For remainder of 2025 and FY26, average reduction is 14% decrease for ambulatory and 24% reduction for non-ambulatory use, says Piper.